A Single Ascending Dose and Relative Bioavailability Study of LY2584702 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 11 Oct 2011
At a glance
- Drugs LY 2584702 (Primary)
- Indications Solid tumours
- Focus Biomarker; Pharmacokinetics
- Sponsors Eli Lilly
- 11 Oct 2011 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jul 2011 Planned End Date changed from 1 Aug 2011 to 1 Sep 2011 as reported by ClinicalTrials.gov.
- 15 Jun 2011 New trial record